Biotech News

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

Twist Bioscience Corporation (TWST)Twist Bioscience Corporation2026-02-17 12:00 ESTFinancing

B-Body ® platform complements Twist’s antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery

Twist Bioscience Corporation

Synthetic Biology Platform Twist Bioscience manufactures customizable synthetic DNA and related biological products at scale. Its platform is designed to improve the speed, throughput and precision of research and development workflows. Oligos and Genes Core products include oligonucleotides, genes and complex DNA constructs used by...

Recent company news

TWSTTwist Bioscience Corporation2026-08-05 03:45 EST

Stock data

Close: 109.08 USD
Market cap: 4.37B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

Related news

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Corporation

Recent company news

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026

Stock data